Clinical Trial Update: Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial testing nivolumab and azacitidine with or without ipilimumab for refractory/relapsed or newly diagnosed acute myeloid leukemia has completed enrol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome
• Bilineal Leukemia
• Myelodysplastic Syndrome
• Therapy-related Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2024-11-04